Create a narrative

Agios Pharmaceuticals Community

NasdaqGS:AGIO Community

1 Narratives written by author
0 Comments on narratives written by author
7 Fair Values set on narratives written by author

Create a narrative

Agios Pharmaceuticals

AN

AnalystConsensusTarget

Consensus Narrative from 7 Analysts

PYRUKYND's Upcoming Launches Will Open New Markets But Face Regulatory Hurdles

Key Takeaways Agios's strategic focus on PYRUKYND and a strong early-stage pipeline aims for significant revenue growth and market expansion. Effective capital deployment and a strong balance sheet position Agios to manage product launches and potential earnings growth efficiently.

US$53.17

FV

43.4% undervalued

109.40%

Revenue growth p.a.

0

0

5

3 days ago